

# Research Study Approval

*The research study named therein has been approved by the Administration of Radioactive Substances Advisory Committee (ARSAC) for the administrations of radioactive substances there specified as required under Regulation 11(1)(d) of IR(ME)R 2017 (GB) and IR(ME)(NI)R 2018*

**Date of Approval:** 02/02/2021

**ARSAC Ref :** AA- 880

**IRAS ID:** 282284

## Study Title

ELEVATE: Temozolomide + nivolumab in MGMT deficient oesophagogastric cancer

---

<b>Procedure Code</b>	<b>Nuclide</b>	<b>Chemical</b>
99mTc-48-10	99mTc	erythrocytes

---

## Conditions of approval

1. This approval is issued based on the information provided to ARSAC in the application form and supporting documents
2. This approval is not transferrable
3. This approval does not have an expiry date
4. An application to ARSAC is required for any material change to the research, as defined in the ARSAC Notes for Guidance, which may affect the validity of this approval
5. The applicant or any other person shall not deface or alter this approval in any way